Avesi Partners-backed Danforth Health has acquired Ambit RD, a consultancy focused on rare and specialty disease markets, according to PE Hub. The transaction was reported by PE Hub in an item published one day ago.
Transaction overview
The acquirer in the deal is Danforth Health, and PE Hub described the company as backed by Avesi Partners, according to PE Hub. The acquired business is Ambit RD.
PE Hub categorized the news under “Healthcare” and tagged it “US,” according to PE Hub.
Ambit RD’s focus and positioning
Ambit RD was founded to help biopharma companies navigate commercial challenges in rare and specialty disease markets, according to PE Hub. PE Hub identified Ambit RD as a rare disease consultancy.
Tools and capabilities added to Danforth’s platform
Ambit RD brings AI-powered patient identification and analytics tools to Danforth’s platform, according to PE Hub. PE Hub reported that these AI-powered tools are part of what Ambit RD contributes following the acquisition.
What PE Hub reported and what it did not
PE Hub reported the acquisition but did not provide financial terms in the available text. PE Hub’s item also did not disclose a purchase price, valuation, or deal size in the available text.
(As general context, acquisitions are commonly used by healthcare and life sciences services platforms to add capabilities such as analytics and patient identification tools.)
